These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18627399)

  • 21. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis.
    Haberer JE; Da-Cruz AM; Soong L; Oliveira-Neto MP; Rivas L; McMahon-Pratt D; Coutinho SG
    Infect Immun; 1998 Jul; 66(7):3100-5. PubMed ID: 9632572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia.
    Silveira FT; Blackwell JM; Ishikawa EA; Braga R; Shaw JJ; Quinnell RJ; Soong L; Kima P; McMahon-Pratt D; Black GF; Shaw MA
    Parasite Immunol; 1998 Jan; 20(1):19-26. PubMed ID: 9491414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection.
    Carvalho GB; Costa LE; Lage DP; Ramos FF; Santos TTO; Ribeiro PAF; Dias DS; Salles BCS; Lima MP; Carvalho LM; Dias ACS; Alves PT; Franklin ML; Silva RAM; Duarte MC; Menezes-Souza D; Roatt BM; Chávez-Fumagalli MA; Goulart LR; Teixeira AL; Coelho EAF
    Parasitology; 2019 Mar; 146(3):322-332. PubMed ID: 30198459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients.
    Carvalho LP; Passos S; Dutra WO; Soto M; Alonso C; Gollob KJ; Carvalho EM; Ribeiro de Jesus A
    Scand J Immunol; 2005 Apr; 61(4):337-42. PubMed ID: 15853916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
    Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term protection conferred by Leishvacin® against experimental Leishmania amazonensis infection in C57BL/6 mice.
    Carneiro MB; de Andrade e Sousa LM; Vaz LG; Dos Santos LM; Vilela L; de Souza CC; Gonçalves R; Tafuri WL; Afonso LC; Côrtes DF; Vieira LQ
    Parasitol Int; 2014 Dec; 63(6):826-34. PubMed ID: 25102355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients.
    Cabrera M; Blackwell JM; Castes M; Trujillo D; Convit J; Shaw MA
    Parasite Immunol; 2000 Feb; 22(2):73-9. PubMed ID: 10652119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8+ T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40(-/-) C57BL/6 mice.
    Hernández Sanabria MX; Afonso LC; Golgher D; Tafuri WL; Vieira LQ
    Microbes Infect; 2007 Jul; 9(9):1124-34. PubMed ID: 17662634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Khademi SZ
    Malays J Pathol; 2017 Dec; 39(3):267-275. PubMed ID: 29279589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IFNG +874T/A polymorphism is not associated with American tegumentary leishmaniasis susceptibility but can influence Leishmania induced IFN-gamma production.
    Matos GI; Covas Cde J; Bittar Rde C; Gomes-Silva A; Marques F; Maniero VC; Amato VS; Oliveira-Neto MP; Mattos Mda S; Pirmez C; Sampaio EP; Moraes MO; Da-Cruz AM
    BMC Infect Dis; 2007 Apr; 7():33. PubMed ID: 17456233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
    Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
    Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.
    Castellano LR; Filho DC; Argiro L; Dessein H; Prata A; Dessein A; Rodrigues V
    Hum Immunol; 2009 Jun; 70(6):383-90. PubMed ID: 19480861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis.
    Singh OP; Stober CB; Singh AK; Blackwell JM; Sundar S
    PLoS Negl Trop Dis; 2012; 6(10):e1874. PubMed ID: 23150744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
    J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of Th1-type responses in mucosal leishmaniasis patients.
    Bacellar O; Lessa H; Schriefer A; Machado P; Ribeiro de Jesus A; Dutra WO; Gollob KJ; Carvalho EM
    Infect Immun; 2002 Dec; 70(12):6734-40. PubMed ID: 12438348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.